Eli Lilly Bets €2.4B on AI-Designed Drugs in New Insilico Medicine Deal

oncodaily - In a sweeping push to expand its pipeline and embrace artificial intelligence in drug discovery, Eli Lilly and Company has announced two major strategic moves: a multi-billion-dollar collaboration with Insilico […]

AI Summary: Eli Lilly struck a major partnership with Insilico Medicine to accelerate AI‑designed drug programs, providing a substantial upfront payment and committing to multiyear development milestones and potential payouts worth roughly in the billions. The deal expands Lilly’s AI drug discovery footprint and signals big pharma’s growing bet on algorithmic chemistry.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Generate Biomedicines prices $400M IPO, spotlights AI drug design / 3 months

Kailera plans IPO for obesity drug aiming to challenge Zepbound / 2 months

Avalyn upsizes IPO to raise cash for lung drug trials / 29 days

Keratin 16 restrains skin inflammation and may guide treatments / 7 wks

Carolyn Bertozzi Returns to Eli Lilly Board / 5 months

Chiesi acquires KalVista for $1.9B to bolster rare disease pipeline / 29 days

Eli Lilly buys Centessa for $6.3B to enter sleep disorder market / 2 months